Skip to content

Net Income at other companies

Merck & Co. logo
Merck & Co.MRK
-$4.24B-183%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$727.2M-10.1%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$88.61M-38.3%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$58.16M-1.2%
HRO
HarrowHROW
-$27.6M-55.2%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$4.93M+63.7%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+189%
Enterprise value$1.15B+228%
P/S158.5×+151×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's net income?
EyePoint, Inc. (EYPT) reported net income of -$84.83M in Q1 2026.
How has EyePoint, Inc. 's net income changed year-over-year?
EyePoint, Inc. 's net income decreased by 87.7% year-over-year, from -$45.2M to -$84.83M.
What is the long-term trend for EyePoint, Inc. 's net income?
Over 4 years (2021 to 2025), EyePoint, Inc. 's net income has grown at a 41.2% compound annual growth rate (CAGR), from -$58.42M to -$231.96M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.